This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
cancer: Archive
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
by Kinjel Shah
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change ABBVPositive Net Change FHTXPositive Net Change IBRXNegative Net Change
cancer pharmaceuticals
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
by Kinjel Shah
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change ABBVPositive Net Change FATEPositive Net Change VSTMPositive Net Change RLAYPositive Net Change
cancer pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
by Kinjel Shah
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
BMYPositive Net Change PFEPositive Net Change LLYNegative Net Change ABBVPositive Net Change ALLOPositive Net Change RLAYPositive Net Change PYXSPositive Net Change
cancer pharmaceuticals
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
by Kinjel Shah
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
AZNPositive Net Change MRKPositive Net Change SMMTNegative Net Change
cancer pharmaceuticals
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
by Kinjel Shah
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
AZNPositive Net Change NVSPositive Net Change JNJPositive Net Change PFEPositive Net Change LLYNegative Net Change ABBVPositive Net Change ALLOPositive Net Change
cancer
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
by Urmimala Biswas
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
AZNPositive Net Change GHNegative Net Change TEMNegative Net Change
artificial-intelligence biotechnology cancer earnings-outlook healthcare medical
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXNegative Net Change BEAMNegative Net Change NTLAPositive Net Change CRSPNegative Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
AZNPositive Net Change NVSPositive Net Change BMYPositive Net Change PFEPositive Net Change LLYNegative Net Change ABBVPositive Net Change FATEPositive Net Change
biotechs cancer pharmaceuticals